Short Interest in Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Expands By 69.2%

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 473,700 shares, a growth of 69.2% from the December 15th total of 279,900 shares. Based on an average daily volume of 582,700 shares, the short-interest ratio is presently 0.8 days. Currently, 2.8% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inspira Technologies Oxy B.H.N. stock. Renaissance Technologies LLC acquired a new position in Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 24,497 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned approximately 0.19% of Inspira Technologies Oxy B.H.N. as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 12.72% of the company’s stock.

Inspira Technologies Oxy B.H.N. Stock Up 0.5 %

Shares of Inspira Technologies Oxy B.H.N. stock traded up $0.01 during mid-day trading on Friday, reaching $1.07. 302,133 shares of the stock were exchanged, compared to its average volume of 2,960,026. Inspira Technologies Oxy B.H.N. has a fifty-two week low of $0.80 and a fifty-two week high of $2.45. The company has a current ratio of 2.23, a quick ratio of 2.13 and a debt-to-equity ratio of 0.09. The firm has a 50-day simple moving average of $1.18 and a 200 day simple moving average of $1.20.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.